Sector News

Actelion CEO says Basilea purchase would make no sense: paper

January 18, 2016
Life sciences

(Reuters) – Swiss drug maker Actelion’s chief executive quashed speculation over its possible interest in purchasing Basilea Pharmaceutica.

“Basilea has developed interesting medications. But the company already has a partner,” Chief Executive Jean-Paul Clozel was quoted as saying in an interview published on Swiss paper Finanz und Wirtschaft’s website on Friday.

“Since we’re interested in active substances and not financial opportunities, it wouldn’t make sense for us to buy Basilea.”

(Reporting by Brenna Hughes Neghaiwi)

comments closed

Related News

September 17, 2022

Novo Nordisk partners with Microsoft for AI-driven drug discovery

Life sciences

Novo Nordisk has signed a new strategic partnership with Microsoft to expedite the discovery and development of drugs leveraging big data and artificial intelligence (AI). Under the deal, Microsoft’s computational services, Cloud and artificial intelligence (AI) will be merged with the drug discovery, development and data science expertise of Novo Nordisk.

September 17, 2022

Bayer’s hunt for a new CEO is on, suggesting Werner Baumann could be headed for an early exit: report

Life sciences

Following years of push-and-pull over the German conglomerate’s top post, Bayer has quietly started a hunt for Baumann’s successor, Bloomberg News reported Tuesday, citing people close to the matter. The new CEO search may portend an early departure for Baumann, whose contract with Bayer isn’t set to expire until April 2024.

September 17, 2022

Bluebird CFO resigns ahead of gene therapy launch

Life sciences

Bluebird bio on Monday said its chief strategy and financial officer, Jason Cole, will leave the company this fall, marking the second time in less than a year the cash-strapped gene therapy developer will replace its top financial executive.